At entry to the cohort, patients were aged 71.8 ± 12.7 years; they had BMI of 25.5 ± 5.3 kg/m2, and 15 % were classified as obese
(Table 1). The rate of smoking was 20 %. Time since diagnosis of osteoporosis was 21.5 ± 49.2 months. About half were receiving cardiovascular treatments such as antihypertensives or platelet ��-Nicotinamide order inhibitors. Two thirds of the patients were receiving calcium and vitamin D supplementation. Fig. 1 Patient flow. MI myocardial infarction, UTS CPRD up-to-standard Clinical Practice Research Datalink (data) Table 1 Characteristics of the cohort of women with treated osteoporosis at cohort entry date, and for women receiving strontium ranelate and women receiving S3I-201 cost alendronate at date of initiation of treatment Women with treated
osteoporosis Women receiving strontium ranelate during follow-up Women receiving alendronate during follow-up N = 112,445 N = 6,487 N = 94,654 Age, years 71.8 ± 12.7 74.9 ± 11.5 72.0 ± 12.5 Body mass index, kg/m2 25.5 ± 5.3 24.6 ± 5.0 25.5 ± 5.3 Smoking 22,820 (20 %) 894 (14 %) 18,554 (20 %) Characteristics of osteoporosis Time since diagnosis, months 21.5 ± 49.2 (median, 0.4) 43.6 ± 57.5 (median, 21.3) 23.2 ± 49.1 (median, 0.5) Calcium supplementation at entry 75,631 (67 %) 4,786 (74 %) 64,721 (68 %) Vitamin D supplementation at entry 69,079 (61 %) 4,614 (71 %) 61,139 JQ1 solubility dmso (65 %) History of cardiovascular events Myocardial infarction 4,502 (4 %) 309 (5 %) 3,740 (4 %) Acute ischaemic cardiac eventa 6,524 (6 %) 447 (7 %) 5,464 (6 %) Treatments at entry ROS1 Antidiabetic agents 6,747 (6 %) 343 (5 %) 5,806 (6 %) Statins/fibrates 26,510 (24 %) 1,710 (26 %) 23,503 (25 %) Antihypertensive agents 57,546 (51 %) 3,472 (54 %) 48,861 (52 %) Platelet inhibitors (including aspirin)
27,381 (24 %) 1,723 (27 %) 23,248 (25 %) Values are means ± SD or numbers (%) aCardiovascular procedure or ischaemic cardiac event (myocardial infarction, acute coronary syndrome, or unstable angina) During the follow-up period, 6,487 patients received strontium ranelate and 94,654 received alendronate. The mean cumulative exposure for strontium ranelate was 12.8 ± 16.4 months (with a maximum of 87 months), while that for alendronate was 25.4 ± 26.0 months. The patients receiving strontium ranelate were older than the general cohort of women with treated osteoporosis and had a longer time since diagnosis; they were also more likely to be receiving concomitant supplementation with calcium and vitamin D (Table 1). There were 1,352 cases of first definite MI in the cohort of women with treated osteoporosis (IR 3.24 per 1,000 patient-years; 95 % CI, 3.07–3.41). Of these, 16 cases were excluded from the analysis due to failure to identify six to ten matching controls, leaving 1,336 cases and 13,330 matching controls.